Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper Jensen

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Circulation|June 1, 2021
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Cardiovascular Diabetology|October 17, 2020
MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fractionJesper Jensen, Morten Schou, Caroline Kistorp, et al.
JACC. Heart Failure|September 12, 2021
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart FailureMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
American Heart Journal Plus : Cardiology Research and Practice|March 21, 2024
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trialJulie Hempel Larsen, Massar Omar, Jesper Jensen, et al.
Cardiovascular Diabetology|February 27, 2022
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)Massar Omar, Jesper Jensen, Caroline Kistorp, et al.
Circulation. Heart Failure|November 8, 2021
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Daniel Burkhoff, et al.
American Heart Journal|August 29, 2024
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health statusCamilla Fuchs Andersen, Massar Omar, Julie Hempel Larsen, et al.
Pediatric Transplantation|October 22, 2019
Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignanciesEliska Furlong, Jesper Jensen, Mark Woodard, et al.
The Lancet Regional Health. Europe|June 2, 2023
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021Mariam Elmegaard Malik, Alexander Christian Falkentoft, Jesper Jensen, et al.
International Journal of Cardiology. Heart & Vasculature|September 4, 2024
Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial)Anna Tuxen, Morten Malmborg, Nina Nouravesh, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Circulation|June 1, 2021
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)Jesper Jensen, Massar Omar, Caroline Kistorp, et al.
Cardiovascular Diabetology|October 17, 2020
MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fractionJesper Jensen, Morten Schou, Caroline Kistorp, et al.
JACC. Heart Failure|September 12, 2021
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart FailureMassar Omar, Jesper Jensen, Peter H Frederiksen, et al.
American Heart Journal Plus : Cardiology Research and Practice|March 21, 2024
Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trialJulie Hempel Larsen, Massar Omar, Jesper Jensen, et al.
Cardiovascular Diabetology|February 27, 2022
The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)Massar Omar, Jesper Jensen, Caroline Kistorp, et al.
Circulation. Heart Failure|November 8, 2021
Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical TrialMassar Omar, Jesper Jensen, Daniel Burkhoff, et al.
American Heart Journal|August 29, 2024
Accelerometer-measured physical activity in patients with heart failure and reduced ejection fraction: Determinants and relationship with patient-reported health statusCamilla Fuchs Andersen, Massar Omar, Julie Hempel Larsen, et al.
Pediatric Transplantation|October 22, 2019
Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignanciesEliska Furlong, Jesper Jensen, Mark Woodard, et al.
The Lancet Regional Health. Europe|June 2, 2023
Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021Mariam Elmegaard Malik, Alexander Christian Falkentoft, Jesper Jensen, et al.
International Journal of Cardiology. Heart & Vasculature|September 4, 2024
Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial)Anna Tuxen, Morten Malmborg, Nina Nouravesh, et al.
Pageof 8